{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellcept&page=9", "query": { "intervention": "Cellcept", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 696, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellcept&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellcept&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T10:00:58.586Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01487577", "title": "Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allogeneic Blood and Marrow Transplantation (BMT)", "Graft Versus Host Disease" ], "interventions": [ { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 19, "start_date": "2010-06", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2016-06-21", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01487577" }, { "nct_id": "NCT03229265", "title": "Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hyperkalemia", "Kidney Transplant" ], "interventions": [ { "name": "Patiromer", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Rogosin Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2017-08-01", "completion_date": "2019-08-07", "has_results": false, "last_update_posted_date": "2020-04-13", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03229265" }, { "nct_id": "NCT06280950", "title": "Expanding Liver Transplant Immunosuppression Minimization Via Everolimus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus (continued reduction)", "type": "DRUG" }, { "name": "Tacrolimus (maintain 50% reduction)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2024-09-12", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06280950" }, { "nct_id": "NCT04903054", "title": "Selective CD28 Blockade in Renal Transplant Recipients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation", "Renal Transplant Recipients" ], "interventions": [ { "name": "Lulizumab", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Thymoglobulin®", "type": "BIOLOGICAL" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2022-01-10", "completion_date": "2022-09-22", "has_results": false, "last_update_posted_date": "2023-03-22", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04903054" }, { "nct_id": "NCT00412360", "title": "Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Natural Killer Cell Lymphoblastic Leukemia/Lymphoma" ], "interventions": [ { "name": "Single Umbilical Cord Blood Unit Transplant", "type": "BIOLOGICAL" }, { "name": "Double Umbilical Cord Blood Unit Transplant", "type": "BIOLOGICAL" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclosporine A", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 224, "start_date": "2006-12", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412360" }, { "nct_id": "NCT01093586", "title": "Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Erythroleukemia (M6a)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Adult Pure Erythroid Leukemia (M6b)", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Burkitt Lymphoma", "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Secondary Myelofibrosis", "Splenic Marginal Zone Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "double-unit umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "cytogenetic analysis", "type": "OTHER" }, { "name": "bone marrow aspiration", "type": "PROCEDURE" }, { "name": "fluorescence in situ hybridization", "type": "OTHER" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "12 Years to 64 Years" }, "enrollment_count": 14, "start_date": "2007-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01093586" }, { "nct_id": "NCT01954784", "title": "Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-10-07", "completion_date": "2017-01-30", "has_results": false, "last_update_posted_date": "2017-02-17", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954784" }, { "nct_id": "NCT01656135", "title": "Reference Group Trial for The ONE Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End-stage Renal Failure", "Kidney Graft Rejection" ], "interventions": [ { "name": "Blood drawing for immune monitoring and questionnaires", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Regensburg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2012-12", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-03-09", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 2, "location_summary": "San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656135" }, { "nct_id": "NCT01085097", "title": "A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Laquinimod", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Prednisolone/Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 46, "start_date": "2010-09-01", "completion_date": "2012-10-24", "has_results": true, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 14, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Leandro", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01085097" }, { "nct_id": "NCT01369082", "title": "Extended Follow-Up After Islet Transplantation in T1D", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type 1 Diabetes (T1D)", "Islet Transplantation" ], "interventions": [ { "name": "Maintenance Immunosuppressive Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2011-05", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-11-13T10:00:58.586Z", "location_count": 8, "location_summary": "San Francisco, California • Miami, Florida • Atlanta, Georgia + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369082" } ] }